<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36472686</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>A novel homozygous p.Ser69Pro SOD1 mutation causes severe young-onset ALS with decreased enzyme activity.</ArticleTitle><Pagination><StartPage>1770</StartPage><EndPage>1773</EndPage><MedlinePgn>1770-1773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11489-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The dose-effect of various SOD1 mutations on SOD1 enzymatic activity offers valuable insights into ALS pathogenesis with possible therapeutic implications. Homozygous SOD1 mutations, yet scarce, are of special interest. We report a novel homozygous SOD1 mutation with decreased enzymatic activity and severe early onset ALS phenotype.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Whole exome sequencing and targeted screening of commonly implicated genes were conducted. Repeat-primed PCR and fragment length analysis were used for C9orf72. Bi-directional Sanger sequencing was used for SOD1 and other genes. SOD1 activity was measured by direct spectrophotometry. Serum neurofilament light chain level was measured by the ELLA immunoassay system.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The homozygous patient for a novel SOD1 variant p.Ser69Pro showed poor SOD1 enzymatic activity (16% of controls) and an early onset ALS phenotype predominantly affecting lower motor neurons with rapid involvement of the trunk, upper limbs and bulbar muscles. The asymptomatic heterozygous relatives had at least 68% of normal enzyme activity. Level of serum neurofilament light chain was much higher (148&#xa0;pg/ml) in the patient than the relatives who had normal levels (6-10&#xa0;pg/ml).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This novel mutation adds knowledge to the ALS genotype-phenotype spectrum and supports the strong dose-effect of SOD1 mutations associated with severely decreased enzymatic activity.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fahmy</LastName><ForeName>Nagia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8670-0419</Identifier><AffiliationInfo><Affiliation>Neuromuscular Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt. dr.nagiafahmy@med.asu.edu.eg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular Research Unit, Neuropsychiatry Department, Faculty of Medicine, Ain Shams University, Cairo, 11566, Egypt. dr.nagiafahmy@med.asu.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Human Genetics, Ulm University, Ulm University Medical Center, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter Munch</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marklund</LastName><ForeName>Stefan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Medical Bioscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-5401-0904</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Ulm Site, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdi</LastName><ForeName>Nabila</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Molecular Pathology Unit, The German University in Cairo, Cairo, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enzyme activity</Keyword><Keyword MajorTopicYN="N">Homozygous</Keyword><Keyword MajorTopicYN="N">Novel mutation</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">Young-onset</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36472686</ArticleId><ArticleId IdType="pmc">PMC9971132</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11489-x</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11489-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marklund S. Spectrophotometric study of spontaneous disproportionation of superoxide anion radical and sensitive direct assay for superoxide dismutase. J Biol Chem. 1976;251(23):7504&#x2013;7507. doi: 10.1016/S0021-9258(17)32878-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)32878-8</ArticleId><ArticleId IdType="pubmed">12168</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna-Yasek DM, et al. SOD1 suppression with Adeno-Associated Virus and MicroRNA in familial ALS. N Engl J Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Nilsson P, Keranen ML, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain. 1997;120(Pt 10):1723&#x2013;1737. doi: 10.1093/brain/120.10.1723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.10.1723</ArticleId><ArticleId IdType="pubmed">9365366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Aoki M, Ohta M, et al. Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial amyotrophic lateral sclerosis with the homozygous mutation. Neurosci Lett. 2001;312:165&#x2013;168. doi: 10.1016/S0304-3940(01)02212-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02212-1</ArticleId><ArticleId IdType="pubmed">11602336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward C, Brock DJ, Minns RA, Swingler RJ. Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet. 1998;35:174. doi: 10.1136/jmg.35.2.174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.35.2.174</ArticleId><ArticleId IdType="pmc">PMC1051232</ArticleId><ArticleId IdType="pubmed">9556377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozoguz A, Uyan O, Birdal G, et al. The distinct genetic pattern of ALS in Turkey and novel mutations. Neurobiol Aging. 2015;36(1764):e9&#x2013;e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6591733</ArticleId><ArticleId IdType="pubmed">25681989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D, Ahmadinejad M, Del-Bo R, et al. Homozygous SOD1 variation L144S produces a severe form of amyotrophic lateral sclerosis in an Iranian family. Neurol Genet. 2022;8:e645. doi: 10.1212/NXG.0000000000000645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000645</ArticleId><ArticleId IdType="pmc">PMC8678909</ArticleId><ArticleId IdType="pubmed">34926808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>